Serotonin model of schizophrenia: emerging role of glutamate mechanisms

The serotonin (5-HT) hypothesis of schizophrenia arose from early studies on interactions between the hallucinogenic drug LSD (D-lysergic acid diethylamide) and 5-HT in peripheral systems. More recent studies have shown that the two major classes of psychedelic hallucinogens, the indoleamines (e.g., LSD) and phenethylamines (e.g. , mescaline), produce their central effects through a common action upon 5-HT(2) receptors. This review focuses on two brain regions, the locus coeruleus and the cerebral cortex, where the actions of indoleamine and the phenethylamine hallucinogens have been shown to be mediated by 5-HT(2A) receptors; in each case, the hallucinogens (via 5-HT(2A) receptors) have been found to enhance glutamatergic transmission. In the prefrontal cortex, 5-HT(2A)-receptors stimulation increases the release of glutamate, as indicated by a marked increase in the frequency of excitatory postsynaptic potentials/currents (EPSPs/EPSCs) in the apical dendritic region of layer V pyramidal cells; this effect is blocked by inhibitory group II/III metabotropic glutamate agonists acting presynaptically and by an AMPA/kainate glutamate antagonist, acting postsynaptically at non-NMDA glutamate receptors. A major alternative drug model of schizophrenia, previously believed to be entirely distinct from that of the psychedelic hallucinogens, is based on the psychotomimetic properties of antagonists of the NMDA subtype of glutamate receptor (e.g., phencylidine and ketamine). However, recently it has been found that many of the effects of the NMDA antagonists may also (1) involve 5-HT(2A) receptors and (2) be mediated through excess activity at non-NMDA (i.e., AMPA/kainate) glutamate receptors. Moreover, pharmacological manipulations of glutamate transmission (e. g., by inhibitory metabotropic glutamate agonists) provide unexpected parallels between the actions of these two classes of drugs. Given an emerging recognition of the importance of alterations in glutamatergic transmission in the actions of both psychedelic hallucinogens an NMDA antagonists, this review concludes with of implications for the pathophysiology and therapy of schizophrenia.

[1]  Marie-Laure Paillère-Martinot,et al.  No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET , 1998, Schizophrenia Research.

[2]  J. Smythies,et al.  Schizophrenia: a new approach. , 1952, The Journal of mental science.

[3]  R. Mailman,et al.  Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation , 1998, Brain Research.

[4]  T. Kameyama,et al.  Phencyclidine-induced head-weaving and head-twitch through interaction with 5-HT1 and 5-HT2 receptors in reserpinized rats , 1987, Neuropharmacology.

[5]  F. Vollenweider,et al.  Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis , 1997, Neuropsychopharmacology.

[6]  D. Schoepp,et al.  Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. , 1998, The Journal of pharmacology and experimental therapeutics.

[7]  M. Nöthen,et al.  Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene , 1996, The Lancet.

[8]  J. Axelrod.  The enzymatic N-methylation of serotonin and other amines. , 1962, The Journal of pharmacology and experimental therapeutics.

[9]  G. Aghajanian,et al.  Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[10]  F. Vollenweider,et al.  Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG) , 1997, European Neuropsychopharmacology.

[11]  J. Axelrod.  Enzymatic Formation of Psychotomimetic Metabolites from Normally Occurring Compounds , 1961, Science.

[12]  S. Hjorth,et al.  Systemic PCP treatment elevates brain extracellular 5‐HT: a microdialysis study in awake rats , 1998, Neuroreport.

[13]  Klaus P. Ebmeier,et al.  Single-photon emission computed tomography with 99mTc-exametazime in unmediated schizophrenic patients , 1993, Biological Psychiatry.

[14]  J. Gaddum,et al.  Drugs which antagonize 5-hydroxytryptamine. , 1954, British journal of pharmacology and chemotherapy.

[15]  R. Glennon,et al.  Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. , 1984, Life sciences.

[16]  F. Bloom,et al.  Lysergic acid diethylamide and serotonin: direct actions on serotonin-containing neurons in rat brain. , 1972, Life sciences. Pt. 1: Physiology and pharmacology.

[17]  J. Krystal,et al.  The NMDA antagonist model for schizophrenia: promise and pitfalls. , 1998, Pharmacopsychiatry.

[18]  C. Léránth,et al.  Catecholaminergic, GABAergic, and hippocamposeptal innervation of gabaergic “somatospiny” neurons in the rat lateral septal area , 1990, The Journal of comparative neurology.

[19]  A. Catafau,et al.  Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: A resting and activation SPECT study , 1994, Psychiatry Research: Neuroimaging.

[20]  S. Snyder,et al.  Neurotransmitter receptors in frontal cortex of schizophrenics. , 1979, Archives of general psychiatry.

[21]  J. Palacios,et al.  Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors , 1985, Brain Research.

[22]  W. Foote,et al.  Lysergic Acid Diethylamide: Sensitive Neuronal Units in the Midbrain Raphe , 1968, Science.

[23]  A Carlsson,et al.  The current status of the dopamine hypothesis of schizophrenia. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[24]  G. Aghajanian,et al.  Mescaline and LSD: direct and indirect effects on serotonin-containing neurons in brain. , 1973, European journal of pharmacology.

[25]  G. Aghajanian.  Mescaline and LSD facilitate the activation of locus coeruleus neurons by peripheral stimuli , 1980, Brain Research.

[26]  S. Hamada,et al.  Localization of 5-HT2A receptor in rat cerebral cortex and olfactory system revealed by immunohistochemistry using two antibodies raised in rabbit and chicken. , 1998, Brain research. Molecular brain research.

[27]  Aghajanian Gk,et al.  Hallucinogenic indoleamines: Preferential action upon presynaptic serotonin receptors. , 1975 .

[28]  E. Gouzoulis-Mayfrank,et al.  History, rationale and potential of human experimental hallucinogenic drug research in psychiatry. , 1998, Pharmacopsychiatry.

[29]  T. Südhof,et al.  Distinct Ca2+ and Sr2+ Binding Properties of Synaptotagmins , 1995, The Journal of Biological Chemistry.

[30]  A. Deutch,et al.  Serotonin 5‐HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex , 1997, Synapse.

[31]  Bita Moghaddam,et al.  Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.

[32]  R. North,et al.  Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex. , 1993, Journal of neurophysiology.

[33]  A. Malhotra,et al.  Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. , 1997, The American journal of psychiatry.

[34]  M. Pompeiano,et al.  Localization of the mRNA for the 5-HT2 receptor by in situ hybridization histochemistry. Correlation with the distribution of receptor sites , 1990, Brain Research.

[35]  A. Carlsson,et al.  Rodent data and general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone , 1998, Journal of Neural Transmission.

[36]  G. Aghajanian,et al.  5-HT2A receptor or alpha1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. , 1999, European journal of pharmacology.

[37]  J. Palacios,et al.  Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907 , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[38]  G. Aghajanian,et al.  Effect of hallucinogens on spontaneous and sensory-evoked locus coeruleus unit activity in the rat: reversal by selective 5-HT2antagonists , 1986, Brain Research.

[39]  G. Aghajanian,et al.  Serotonin Induces Excitatory Postsynaptic Potentials in Apical Dendrites of Neocortical Pyramidal Cells , 1997, Neuropharmacology.

[40]  C. Tamminga.  Serotonin and schizophrenia. , 1998, Biological psychiatry.

[41]  N. Andreasen,et al.  Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naïve patients , 1997, The Lancet.

[42]  M. Spitzer,et al.  Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: Experimental psychosis as a tool for psychiatric research , 1992, Biological Psychiatry.

[43]  J. Joyce,et al.  Alterations in the cortical serotonergic system in schizophrenia: A postmortem study , 1997, Biological Psychiatry.

[44]  B. Moghaddam,et al.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.

[45]  M. Molliver,et al.  Correspondence between 5-HT2 receptors and serotonergic axons in rat neocortex , 1988, Brain Research.

[46]  E. sanders-Bush,et al.  Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. , 1988, The Journal of pharmacology and experimental therapeutics.

[47]  D. Schoepp,et al.  LY354740 is a Potent and Highly Selective Group II Metabotropic Glutamate Receptor Agonist in Cells Expressing Human Glutamate Receptors , 1997, Neuropharmacology.

[48]  N. Lindefors,et al.  Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex , 1997, Brain Research.

[49]  G. Aghajanian,et al.  5-Hydroxytryptamine-induced excitatory postsynaptic currents in neocortical layer V pyramidal cells: suppression by μ-opiate receptor activation , 1998, Neuroscience.

[50]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[51]  H. Meltzer,et al.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.

[52]  R. Glennon.  Do classical hallucinogens act as 5-HT2 agonists or antagonists? , 1990, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[53]  A. Balestrieri,et al.  Acquired and crossed tolerance to mescaline, LSD-25, and BOL-148. , 1959, A.M.A. archives of general psychiatry.

[54]  D R Medoff,et al.  Ketamine activates psychosis and alters limbic blood flow in schizophrenia , 1995, Neuroreport.

[55]  G. Aston-Jones,et al.  A 5-hydroxytryptamine2 agonist augments γ-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neurons , 1993, Neuroscience.

[56]  Y. Goda,et al.  Two components of transmitter release at a central synapse. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[57]  F Xavier Castellanos,et al.  Cerebrospinal Fluid Homovanillic Acid Predicts Behavioral Response to Stimulants in 45 Boys with Attention Deficit/Hyperactivity Disorder , 1996, Neuropsychopharmacology.

[58]  R. Andrade,et al.  5-Hydroxytryptamine2 and 5-hydroxytryptamine1A receptors mediate opposing responses on membrane excitability in rat association cortex , 1991, Neuroscience.

[59]  T. Kuno,et al.  Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics , 1986, Biological Psychiatry.

[60]  G. Aghajanian,et al.  Activation of locus coeruleus neurons by peripheral stimuli: modulation by a collateral inhibitory mechanism. , 1978, Life sciences.

[61]  D. Woolley,et al.  Some serotoninlike activities of lysergic acid diethylamide. , 1956, Science.

[62]  C. Nahmias,et al.  Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia , 1989, Psychiatry Research.

[63]  G. Pearlson.  Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. , 1981, The Johns Hopkins medical journal.

[64]  T. Svensson,et al.  Non‐NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK‐801) induced hyperlocomotion and dopamine release in the nucleus accumbens , 1998, Journal of neuroscience research.

[65]  G. Aghajanian,et al.  Serotonin (5-HT) induces IPSPs in pyramidal layer cells of rat piriform cortex: evidence for the involvement of a 5-HT2 -activated interneuron , 1990, Brain Research.

[66]  G. Aghajanian,et al.  Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release , 1999, Brain Research.

[67]  P P Humphrey,et al.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.

[68]  D. X. Freedman.  Effects of LSD-25 on brain serotonin. , 1961, The Journal of pharmacology and experimental therapeutics.

[69]  D. Woolley,et al.  A BIOCHEMICAL AND PHARMACOLOGICAL SUGGESTION ABOUT CERTAIN MENTAL DISORDERS. , 1954, Proceedings of the National Academy of Sciences of the United States of America.

[70]  M. Raskin,et al.  LSD-25 ACTION IN NORMAL SUBJECTS TREATED WITH A MONOAMINE OXIDASE INHIBITOR. , 1964, Life sciences.

[71]  D. Collier,et al.  Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine , 1998, Molecular Psychiatry.

[72]  L. JakabR,et al.  霊長類大脳皮質の5‐ヒドロキシトリプタミン2Aセロトニン受容体 錐体細胞先端樹状突起での幻覚剤及び抗精神病剤の作用部位 , 1998 .

[73]  C. Altar,et al.  Typical and atypical antipsychotic occupancy of D2 and S2 receptors: An autoradiographic analysis in rat brain , 1986, Brain Research Bulletin.

[74]  Paul J. Harrison,et al.  5-HT1A and 5-HT2A Receptor mRNAs and Binding Site Densities Are Differentially Altered in Schizophrenia , 1996, Neuropsychopharmacology.

[75]  G. Aghajanian,et al.  LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex. , 1996, The Journal of pharmacology and experimental therapeutics.

[76]  A Carlsson,et al.  Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. , 1997, Life sciences.

[77]  M S Buchsbaum,et al.  Decreased anterior cingulate gyrus metabolic rate in schizophrenia. , 1997, The American journal of psychiatry.

[78]  J. Kleinman,et al.  Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. , 1993, Archives of general psychiatry.

[79]  F. Bloom,et al.  Nonrepinephrine-containing locus coeruleus neurons in behaving rats exhibit pronounced responses to non-noxious environmental stimuli , 1981, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[80]  G. Aghajanian,et al.  Serotonin and Hallucinogens , 1999, Neuropsychopharmacology.

[81]  G. Knoll,et al.  Single-photon emission computed tomography , 1983, Proceedings of the IEEE.

[82]  K. Fuxe,et al.  EVIDENCE FOR THE EXISTENCE OF MONOAMINE-CONTAINING NEURONS IN THE CENTRAL NERVOUS SYSTEM. I. DEMONSTRATION OF MONOAMINES IN THE CELL BODIES OF BRAIN STEM NEURONS. , 1964, Acta physiologica Scandinavica. Supplementum.

[83]  W. Kroeze,et al.  The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis , 1998, Biological Psychiatry.

[84]  D. Murphy,et al.  Chronic Administration of Serotonergic Antidepressants Attenuates the Subjective Effects of LSD in Humans , 1996, Neuropsychopharmacology.

[85]  P S Goldman-Rakic,et al.  5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. , 1998, Proceedings of the National Academy of Sciences of the United States of America.